Xiaoqing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoqing Zhang has a total of 385 co-authors. Here are the top co-authors by number of shared publications:
Yi Hui
15 shared publicationsLin Ma
Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, Shanghai, China; Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai, China
13 shared publications- Ling Liu
Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
12 shared publications Yujiang Fang
Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
12 shared publicationsXiangjie Xu
Translational Medical Center for Stem Cell Therapy Shanghai East Hospital School of Medicine Tongji University Shanghai China
11 shared publicationsZhenyu Chen
Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China
11 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Fundamental Research
Combining engineered post-implantation embryoid and xenotransplantation for improved modeling of early human organogenesis
- 1 January 2026
- Published by KEAI Publishing in Fundamental Research
Open AccessCombining engineered post-implantation embryoid and xenotransplantation for improved modeling of early human organogenesis
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Fundamental Research
- Vol. 6 (1) , 521-534
Engineering of rhesus monkey pluripotent stem cells for noninvasive survey and remote control after brain allotransplantation
• Long-term noninvasive survey of rhesus monkey brain allografts harboring build-in stimulatory DREADD with MR imaging, [18F]FDG-PET and EEG. • Achieving remote control over neuronal activity of brain allografts derived from engineered rhesus monkey pluripotent stem cells. • Improving the safety of transplantation in rhesus monkeys via a preset built-in suicide system. • Integration of genetic engineering and cell therapy represents a powerful strategy for the development of controllable cell therapeutics.
- 1 January 2026
- Published by KEAI Publishing in Fundamental Research
- Vol. 6 (1) , 521-534
Open AccessEngineering of rhesus monkey pluripotent stem cells for noninvasive survey and remote control after brain allotransplantation
• Long-term noninvasive survey of rhesus monkey brain allografts harboring build-in stimulatory DREADD with MR imaging, [18F]FDG-PET and EEG. • Achieving remote control over neuronal activity of brain allografts derived from engineered rhesus monkey pluripotent stem cells. • Improving the safety of transplantation in rhesus monkeys via a preset built-in suicide system. • Integration of genetic engineering and cell therapy represents a powerful strategy for the development of controllable cell therapeutics.
- 1 October 2025
- Published by Springer Nature in Nature Cell Biology
- Vol. 27 (10) , 1797-1811
Remodelling bivalent chromatin is essential for mouse peri-implantation embryogenesis
Bivalency regulates developmental genes during lineage commitment. However, mechanisms governing bivalent domain establishment, maintenance and resolution in early embryogenesis remain unclear. Here we comprehensively trace bivalent chromatin remodelling throughout mouse peri-implantation development, revealing bifurcated establishment modes that partition epiblast and primitive endoderm regulatory programmes. We identify transiently maintained bivalent domains (TB domains) enriched in the epiblast, where gradual resolution fine-tunes pluripotency progression. Through targeted screening in embryos, we uncover 22 TB domain regulators, including the essential factor ZBTB17. Genetic ablation or degradation of ZBTB17 causes peri-implantation arrest. Mechanistically, ZBTB17 collaborates with KDM6A/B to resolve bivalency by removing H3K27me3 and priming the activation of key pluripotency genes. Remarkably, TB domain dynamics are evolutionarily shared in human pluripotent transitions, with ZBTB17 involvement despite species differences. Our work establishes a framework for bivalent chromatin regulation in early mammalian development and elucidates how its resolution precisely controls lineage commitment.
- 1 October 2025
- Published by Springer Nature in Nature Cell Biology
- Vol. 27 (10) , 1797-1811
Remodelling bivalent chromatin is essential for mouse peri-implantation embryogenesis
Bivalency regulates developmental genes during lineage commitment. However, mechanisms governing bivalent domain establishment, maintenance and resolution in early embryogenesis remain unclear. Here we comprehensively trace bivalent chromatin remodelling throughout mouse peri-implantation development, revealing bifurcated establishment modes that partition epiblast and primitive endoderm regulatory programmes. We identify transiently maintained bivalent domains (TB domains) enriched in the epiblast, where gradual resolution fine-tunes pluripotency progression. Through targeted screening in embryos, we uncover 22 TB domain regulators, including the essential factor ZBTB17. Genetic ablation or degradation of ZBTB17 causes peri-implantation arrest. Mechanistically, ZBTB17 collaborates with KDM6A/B to resolve bivalency by removing H3K27me3 and priming the activation of key pluripotency genes. Remarkably, TB domain dynamics are evolutionarily shared in human pluripotent transitions, with ZBTB17 involvement despite species differences. Our work establishes a framework for bivalent chromatin regulation in early mammalian development and elucidates how its resolution precisely controls lineage commitment.
- Open Access
- 30 August 2025
- Published by Elsevier in Pharmacological Research
- Vol. 220, 107937
Glia maturation factor-β deficiency improves insulin resistance by promoting CARM1-mediated lipid turnover
- 30 August 2025
- Published by Elsevier in Pharmacological Research
- Vol. 220, 107937
Open AccessGlia maturation factor-β deficiency improves insulin resistance by promoting CARM1-mediated lipid turnover
- Open Access
- 28 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110637
Mapping cellular cytosolic pH in vivo under physiological and pathophysiological conditions
- 28 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110637
Open AccessMapping cellular cytosolic pH in vivo under physiological and pathophysiological conditions
- Open Access
- 3 January 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (2) , 132-144
Donor MHC-specific thymus vaccination allows for immunocompatible allotransplantation
Organ transplantation is the last-resort option to treat organ failure. However, less than 10% of patients benefit from this only option due to lack of major histocompatibility complex (MHC)-matched donor organs and 25%–80% of donated organs could not find MHC-matched recipients. T cell allorecognition is the principal mechanism for allogeneic graft rejection. We herein present a “donor MHC-specific thymus vaccination” (DMTV) strategy to induce T cell tolerance to both autologous and allogeneic donor MHC. Allogeneic MHC molecules were expressed in the recipient thymus through adeno-associated virus-mediated delivery, which led to stable expression of allogeneic MHC together with the autologous MHC in the engineered thymus. During local T cell education, those T cells recognizing either autologous MHC or allogeneic MHC were equally depleted. We constructed C57BL/6-MHC and BALB/c-MHC dual immunocompatible mice via thymus vaccination of C57BL/6-MHC into the BALB/c thymus and observed long-term graft tolerance after transplantation of C57BL/6 skin and C57BL/6 mouse embryonic stem cells into the vaccinated BALB/c mice. We also validated our DMTV strategy in a bone marrow, liver, thymus (BLT)-humanized mouse model for immunocompatible allotransplantation of human embryonic stem cells. Our study suggests that the DMTV strategy is a potent avenue to introduce a donor compatible immune system in recipients, which overcomes the clinical dilemma of the extreme shortage of MHC-matched donor organs for treating patients with end-stage organ failure.
- 3 January 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (2) , 132-144
Open AccessDonor MHC-specific thymus vaccination allows for immunocompatible allotransplantation
Organ transplantation is the last-resort option to treat organ failure. However, less than 10% of patients benefit from this only option due to lack of major histocompatibility complex (MHC)-matched donor organs and 25%–80% of donated organs could not find MHC-matched recipients. T cell allorecognition is the principal mechanism for allogeneic graft rejection. We herein present a “donor MHC-specific thymus vaccination” (DMTV) strategy to induce T cell tolerance to both autologous and allogeneic donor MHC. Allogeneic MHC molecules were expressed in the recipient thymus through adeno-associated virus-mediated delivery, which led to stable expression of allogeneic MHC together with the autologous MHC in the engineered thymus. During local T cell education, those T cells recognizing either autologous MHC or allogeneic MHC were equally depleted. We constructed C57BL/6-MHC and BALB/c-MHC dual immunocompatible mice via thymus vaccination of C57BL/6-MHC into the BALB/c thymus and observed long-term graft tolerance after transplantation of C57BL/6 skin and C57BL/6 mouse embryonic stem cells into the vaccinated BALB/c mice. We also validated our DMTV strategy in a bone marrow, liver, thymus (BLT)-humanized mouse model for immunocompatible allotransplantation of human embryonic stem cells. Our study suggests that the DMTV strategy is a potent avenue to introduce a donor compatible immune system in recipients, which overcomes the clinical dilemma of the extreme shortage of MHC-matched donor organs for treating patients with end-stage organ failure.
- 20 March 2024
- Published by Elsevier in Cell Metabolism
- Vol. 36 (6) , 1237-1251.e4
Cytosolic pH is a direct nexus in linking environmental cues with insulin processing and secretion in pancreatic β cells
- 20 March 2024
- Published by Elsevier in Cell Metabolism
- Vol. 36 (6) , 1237-1251.e4
Cytosolic pH is a direct nexus in linking environmental cues with insulin processing and secretion in pancreatic β cells
- Open Access
- 6 May 2023
- Published by Oxford University Press (OUP) in Life Medicine
- Vol. 2 (3) , lnad017
A framework of biomarkers for brain aging: a consensus statement by the Aging Biomarker Consortium
China and the world are facing severe population aging and an increasing burden of age-related diseases. Aging of the brain causes major age-related brain diseases, such as neurodegenerative diseases and stroke. Identifying biomarkers for the effective assessment of brain aging and establishing a brain aging assessment system could facilitate the development of brain aging intervention strategies and the effective prevention and treatment of aging-related brain diseases. Thus, experts from the Aging Biomarker Consortium (ABC) have combined the latest research results and practical experience to recommend brain aging biomarkers and form an expert consensus, aiming to provide a basis for assessing the degree of brain aging and conducting brain-aging-related research with the ultimate goal of improving the brain health of elderly individuals in both China and the world.
- 6 May 2023
- Published by Oxford University Press (OUP) in Life Medicine
- Vol. 2 (3) , lnad017
Open AccessA framework of biomarkers for brain aging: a consensus statement by the Aging Biomarker Consortium
China and the world are facing severe population aging and an increasing burden of age-related diseases. Aging of the brain causes major age-related brain diseases, such as neurodegenerative diseases and stroke. Identifying biomarkers for the effective assessment of brain aging and establishing a brain aging assessment system could facilitate the development of brain aging intervention strategies and the effective prevention and treatment of aging-related brain diseases. Thus, experts from the Aging Biomarker Consortium (ABC) have combined the latest research results and practical experience to recommend brain aging biomarkers and form an expert consensus, aiming to provide a basis for assessing the degree of brain aging and conducting brain-aging-related research with the ultimate goal of improving the brain health of elderly individuals in both China and the world.
- Open Access
- 6 May 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (5) , 1-11
Overexpression of EphB6 and EphrinB2 controls soma spacing of cortical neurons in a mutual inhibitory way
To establish functional circuitry, neurons settle down in a particular spatial domain by spacing their cell bodies, which requires proper positioning of the soma and establishing of a zone with unique connections. Deficits in this process are implicated in neurodevelopmental diseases. In this study, we examined the function of EphB6 in the development of cerebral cortex. Overexpression of EphB6 via in utero electroporation results in clumping of cortical neurons, while reducing its expression has no effect. In addition, overexpression of EphrinB2, a ligand of EphB6, also induces soma clumping in the cortex. Unexpectedly, the soma clumping phenotypes disappear when both of them are overexpressed in cortical neurons. The mutual inhibitory effect of EphB6/ EphrinB2 on preventing soma clumping is likely to be achieved via interaction of their specific domains. Thus, our results reveal a combinational role of EphrinB2/EphB6 overexpression in controlling soma spacing in cortical development.
- 6 May 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (5) , 1-11
Open AccessOverexpression of EphB6 and EphrinB2 controls soma spacing of cortical neurons in a mutual inhibitory way
To establish functional circuitry, neurons settle down in a particular spatial domain by spacing their cell bodies, which requires proper positioning of the soma and establishing of a zone with unique connections. Deficits in this process are implicated in neurodevelopmental diseases. In this study, we examined the function of EphB6 in the development of cerebral cortex. Overexpression of EphB6 via in utero electroporation results in clumping of cortical neurons, while reducing its expression has no effect. In addition, overexpression of EphrinB2, a ligand of EphB6, also induces soma clumping in the cortex. Unexpectedly, the soma clumping phenotypes disappear when both of them are overexpressed in cortical neurons. The mutual inhibitory effect of EphB6/ EphrinB2 on preventing soma clumping is likely to be achieved via interaction of their specific domains. Thus, our results reveal a combinational role of EphrinB2/EphB6 overexpression in controlling soma spacing in cortical development.
- Open Access
- 24 January 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-15
Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity
Hypoimmunogenic human pluripotent stem cells (hPSCs) are expected to serve as an unlimited cell source for generating universally compatible “off-the-shelf” cell grafts. However, whether the engineered hypoimmunogenic hPSCs still preserve their advantages of unlimited self-renewal and multilineage differentiation to yield functional tissue cells remains unclear. Here, we systematically studied the self-renewal and differentiation potency of three types of hypoimmunogenic hPSCs, established through the biallelic lesion of B2M gene to remove all surface expression of classical and nonclassical HLA class I molecules (B2Mnull), biallelic homologous recombination of nonclassical HLA-G1 to the B2M loci to knockout B2M while expressing membrane-bound β2m-HLA-G1 fusion proteins (B2MmHLAG), and ectopic expression of soluble and secreted β2m-HLA-G5 fusion proteins in B2MmHLAG hPSCs (B2Mm/sHLAG) in the most widely used WA09 human embryonic stem cells. Our results showed that hypoimmunogenic hPSCs with variable expression patterns of HLA molecules and immune compromising spectrums retained their normal self-renewal capacity and three-germ-layer differentiation potency. More importantly, as exemplified by neurons, cardiomyocytes and hepatocytes, hypoimmunogenic hPSC-derived tissue cells were fully functional as of their morphology, electrophysiological properties, macromolecule transportation and metabolic regulation. Our findings thus indicate that engineered hypoimmunogenic hPSCs hold great promise of serving as an unlimited universal cell source for cell therapeutics.
- 24 January 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-15
Open AccessHypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity
Hypoimmunogenic human pluripotent stem cells (hPSCs) are expected to serve as an unlimited cell source for generating universally compatible “off-the-shelf” cell grafts. However, whether the engineered hypoimmunogenic hPSCs still preserve their advantages of unlimited self-renewal and multilineage differentiation to yield functional tissue cells remains unclear. Here, we systematically studied the self-renewal and differentiation potency of three types of hypoimmunogenic hPSCs, established through the biallelic lesion of B2M gene to remove all surface expression of classical and nonclassical HLA class I molecules (B2Mnull), biallelic homologous recombination of nonclassical HLA-G1 to the B2M loci to knockout B2M while expressing membrane-bound β2m-HLA-G1 fusion proteins (B2MmHLAG), and ectopic expression of soluble and secreted β2m-HLA-G5 fusion proteins in B2MmHLAG hPSCs (B2Mm/sHLAG) in the most widely used WA09 human embryonic stem cells. Our results showed that hypoimmunogenic hPSCs with variable expression patterns of HLA molecules and immune compromising spectrums retained their normal self-renewal capacity and three-germ-layer differentiation potency. More importantly, as exemplified by neurons, cardiomyocytes and hepatocytes, hypoimmunogenic hPSC-derived tissue cells were fully functional as of their morphology, electrophysiological properties, macromolecule transportation and metabolic regulation. Our findings thus indicate that engineered hypoimmunogenic hPSCs hold great promise of serving as an unlimited universal cell source for cell therapeutics.